VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: A multicenter experience

Archives of Gerontology and Geriatrics

Volumn 51, Issue 2, 2010, Pages 209-215

  Ishii, Kazuyoshi ^a   Urase, Fumiaki ^b   Nagare, Yasuaki ^b   Kimura, Hidetsugu ^b   Manabe, Masahiro ^c   Yagi, Toshiya ^c   Teshima, Hirofumi ^c   Hayashi, Kunio ^d   Shibano, Masaru ^e   Tsukaguchi, Machiko ^e   Katsurada, Tatsuya ^f   Mugitani, Atsuko ^g   Kitayama, Hitoshi ^h   Nomura, Shosaku ^a  

^a Kishiwada City Hospital   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d Hirakata Kosai Hospital   (Japan)

^e SAKAI MUNICIPAL HOSPITAL   (Japan)

^f TAKEDA GENERAL HOSPITAL   (Japan)

^g Department of Hematology   (Japan)

^h HOSHIGAOKA KOSEINENKIN HOSPITAL   (Japan)

Author keywords

Aggressive B cell non Hodgkin lymphoma; IgG; Treatment of B cell non Hodgkin lymphoma in elderly; VNCOP B plus rituximab

Indexed keywords

BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETOPOSIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MITOXANTRONE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE PERFORATION; LIVER INJURY; LUNG MYCOSIS; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT CODING; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRAL RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA;

EID: 77955279762     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2009.10.010     Document Type: Article

References (34)

1. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002, 346:235-242.
2. Doorduijn J.K., Van der Holt B., Van Imhoff G.W., Van der Hem K.G., Kramer M.H., Van Oers M.H., Ossenkoppele G.J., Schaafsma M.R., Verdonck L.F., Verhoef G.E., Steijaert M.M., Buijt I., Uyl-de Groot C.A., Van Agthoven M., Mulder A.H., Sonneveld P. CHOP compared With CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 2003, 21:3041-3050.
3. Ennishi D., Takeuchi K., Yokoyama M., Asai H., Mishima Y., Terui Y., Takahashi S., Komatsu H., Ikeda K., Yamaguchi M., Suzuki R., Tanimoto M., Hatake K. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann. Oncol. 2008, 19:1921-1926.
4. Epelbaum R., Haim N., Ben-Shahar M., Ron Y., Cohen Y. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr. J. Med. Sci. 1988, 24:533-538.
5. Feugier P., Van Hoof A., Sebban C., Solal-Celigny P., Bouabdallah R., Fermé C., Christian B., Lepage E., Tilly H., Morschhauser F., Gaulard P., Salles G., Bosly A., Gisselbrecht C., Reyes F., Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J. Clin. Oncol. 2005, 23:4117-41126.
6. Fina M., Tani M., Stefoni V., Musuraca G., Marchi E., Pellegrini C., Alinari L., Derenzini E., Bacci F., Pileri S., Baccarani M., Zinzani P.L. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly. Leuk. Lymphoma 2007, 48:2167-2171.
7. Fisher R.I., Gaynor E.R., Dahlberg S., Oken M., Grogan T.M., Mize E.M., Glick J.H., Coltman C.A., Miller T.P. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N. Engl. J. Med. 1993, 328:1002-1006.
8. Forstpointner R., Unterhalt M., Dreyling M., Böck H.P., Repp R., Wandt H., Pott C., Seymour J.F., Metzner B., Hänel A., Lehmann T., Hartmann F., Einsele H., Hiddemann W. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003-4008. German Low Grade Lymphoma Study Group (GLSG).
9. Gómez H., Mas L., Casanova L., Pen D.L., Santillana S., Valdivia S., Otero J., Rodriguez W., Carracedo C., Vallejos C. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J. Clin. Oncol. 1998, 16:2352-2358.
10. Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., Dakhil S.R., Woda B., Fisher R.I., Peterson B.A., Horning S.J. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 2006, 24:3121-3127.
11. Hainsworth J.D., Litchy S., Lamb M.R., Rodriguez G.I., Scroggin C., Greco F.A. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. Clin. Lymphoma 2003, 4:36-42.
12. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 1984, 2:1281-1288.
13. Ishii K., Yamamoto Y., Shigeki T., Kitayama H., Hayashi K., Hirose A., Ohta T., Mugitani A., Fujino H., Yagi T., Hirai M., Teshima H., Katsurada T., Urase F., Kitajima H. VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma. A study of efficacy and safety, final report. Gan To Kagaku Ryoho 2005, 32:39-44. (in Japanese).
14. Jack A.S., Burnett A.K. Procedures for the primary diagnosis and follow-up of patients with lymphoma. Non-Hodgkin's Lymphomas 2004, 81-95. Lippincott Williams and Wilkins, Philadelphia. P.M. Mauch, J.O. Armitage, B. Coiffier, R. Dalla-Favera, N.L. Harris (Eds.).
15. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues 2001, International Agency for Research on Cancer, Lyon, pp. 171-180. E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (Eds.).
16. Komatsu R., Sawada T. The role of international migration in infectious diseases: the HIV epidemic and its trends in Japan. Int. J. Health Serv. 2007, 37:745-759.
17. Kwak L.W., Halpern J., Olshen R.A., Horning S.J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J. Clin. Oncol. 1990, 8:963-977.
18. Lepage E., Gisselbrecht C., Haioun C., Sebban C., Tilly H., Bosly A., Morel P., Herbrecht R., Reyes F., Coiffier B. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann. Oncol. 1993, 4:651-656.
19. Lyman G.H., Dale D.C., Friedberg J., Crawford J., Fisher R.I. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J. Clin. Oncol. 2004, 22:4302-4311.
20. Maloney D.G., Grillo-López A.J., White C.A., Bodkin D., Schilder R.J., Neidhart J.A., Janakiraman N., Foon K.A., Liles T.M., Dallaire B.K., Wey K., Royston I., Davis T., Levy R. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997, 90:2188-2195.
21. McLaughlin P., Grillo-Lopez A.J., Link B.K., Levy R., Czuczman M.S., Williams M.E., Heyman M.R., Bence-Bruckler I., White C.A., Cabanillas F., Jain V., Ho A.D., Lister J., Wey K., Shen D., Dallaire B.K. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 1998, 16:2825-2833.
22. Meyer R.M., Browman G.P., Samosh M.L., Benger A.M., Bryant-Lukosius D., Wilson W.E., Frank G.L., Leber B.F., Sternbach M.S., Foster G.A. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 1995, 13:2386-2393.
23. Ogura M., Morishima Y., Kagami Y., Watanabe T., Itoh K., Igarashi T., Hotta T., Kinoshita T., Ohashi Y., Mori S., Terauchi T., Tobinai K. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. Cancer Sci. 2006, 97:305-312.
24. Osby E., Hagberg H., Kvaløy S., Teerenhovi L., Anderson H., Cavallin-Stahl E., Holte H., Myhre J., Pertovaara H., Björkholm M. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003, 101:3840-3848. Nordic Lymphoma Group.
25. Persky D.O., Unger J.M., Spier C.M., Stea B., LeBlanc M., McCarty M.J., Rimsza L.M., Fisher R.I., Miller T.P. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group Study, 0014. J. Clin. Oncol. 2008, 26:2258-2263. Southwest Oncology Group.
26. Pfreundschuh M., Trümper L., Osterborg A., Pettengell R., Trneny M., Imrie K., Ma D., Gill D., Walewski J., Zinzani P.L., Stahel R., Kvaloy S., Shpilberg O., Jaeger U., Hansen M., Lehtinen T., López-Guillermo A., Corrado C., Scheliga A., Milpied N., Mendila M., Rashford M., Kuhnt E., Loeffler M. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006, 7:379-391. MabThera International Trial Group.
27. Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., Klasa R., Savage K.J., Shenkier T., Sutherland J., Gascoyne R.D., Connors J.M. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-1861.
28. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., Bennett C.L., Cantor S.B., Crawford J., Cross S.J., Demetri G., Desch C.E., Pizzo P.A., Schiffer C.A., Schwartzberg L., Somerfield M.R., Somlo G., Wade J.C., Wade J.L., Winn R.J., Wozniak A.J., Wolff A.C. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J. Clin. Oncol. 2006, 24:3187-3205.
29. The International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma. N. Engl. J. Med. 1993, 329:987-994.
30. The Non-Hodgkin's Lymphoma Classification Project A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997, 89:3909-3918.
31. Tirelli U., Errante D., Van Glabbeke M., Teodorovic I., Kluin-Nelemans J.C., Thomas J., Bron D., Rosti G., Somers R., Zagonel V., Noordijk E.M. CHOP is the standard regimen in patients > or =70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J. Clin. Oncol. 1998, 16:27-34.
32. Van Oers M.H., Klasa R., Marcus R.E., Wolf M., Kimby E., Gascoyne R.D., Jack A., Van't Veer M., Vranovsky A., Holte H., Van Glabbeke M., Teodorovic I., Rozewicz C., Hagenbeek A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295-3301.
33. Váróczy L., Dankó A., Simon Z., Gergely L., Ress Z., Illés A. Malignant lymphomas in the elderly: a single institute experience highlights future directions. Arch. Gerontol. Geriatr. 2007, 45:43-53.
34. Zinzani P.L., Storti S., Zaccaria A., Moretti L., Magagnoli M., Pavone E., Gentilini P., Guardigni L., Gobbi M., Fattori P.P., Falini B., Lauta V.M., Bendandi M., Gherlinzoni F., De Renzo A., Zaja F., Mazza P., Volpe E., Bocchia M., Aitini E., Tabanelli M., Leone G., Tura S. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999, 94:33-38.